ERBB2 and breast carcinoma: This descriptive retrospective study of claims and registry data found that the OS and RFS of HER2-positive breast cancer patients treated with trastuzumab in a clinical practice setting were similar to those previously observed in the B-31/N9831 trials and other randomized and observational studies.